Viruj Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 16-07-2024
- Paid Up Capital ₹ 0.20 M
as on 16-07-2024
- Company Age 10 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.04 Cr
as on 16-07-2024
- Revenue -46.78%
(FY 2023)
- Profit -71.98%
(FY 2023)
- Ebitda -94.41%
(FY 2023)
- Net Worth 8.98%
(FY 2023)
- Total Assets 40.57%
(FY 2023)
About Viruj Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.20 M.
The company currently has active open charges totaling ₹3.04 Cr.
Balasubba Mamilla and Mahesh Pidimarri serve as directors at the Company.
- CIN/LLPIN
U24100TG2014PTC095202
- Company No.
095202
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Aug 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Viruj Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mahesh Pidimarri  | Managing Director | 11-Aug-2014 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Balasubba Mamilla | Director | 11-Aug-2014 | Current |
Financial Performance and Corporate Structure Insights of Viruj Pharmaceuticals.
Viruj Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 46.78% decrease. The company also saw a substantial fall in profitability, with a 71.98% decrease in profit. The company's net worth moved up by a moderate rise of 8.98%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Viruj Pharmaceuticals?
In 2023, Viruj Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Virupaksha Laboratories Private LimitedActive 23 years 10 months
Balasubba Mamilla is a mutual person
Virupaksha Life Sciences LlpActive 6 years 9 monthsBalasubba Mamilla and Mahesh Pidimarri are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 30 Jul 2021 | ₹1.00 M | Open |
Tata Capital Financial Services Limited Creation Date: 30 Nov 2020 | ₹1.85 Cr | Open |
Others Creation Date: 22 Dec 2017 | ₹1.09 Cr | Open |
How Many Employees Work at Viruj Pharmaceuticals?
Viruj Pharmaceuticals has a workforce of 44 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Viruj Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Viruj Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
